公开(公告)号：US20240277674A1

公开(公告)日：2024-08-22

申请号：US18500416

申请日：2023-11-02

Applicant: PanOptica, Inc.

Inventor： David P. BINGAMAN ,  Paul G. CHANEY ,  Martin B. WAX

IPC: A61K31/425 ,  A61K9/00 ,  A61K9/08 ,  A61K9/10 ,  A61K31/00 ,  A61K31/122 ,  A61K31/427 ,  A61K31/455 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P27/02 ,  A61P27/06

CPC classification number: A61K31/425 ,  A61K9/0048 ,  A61K9/08 ,  A61K9/10 ,  A61K31/00 ,  A61K31/122 ,  A61K31/427 ,  A61K31/455 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38 ,  A61P27/02 ,  A61P27/06 ,  A61K2300/00

Abstract: The present application relates to topical formulations comprising Compound-I




or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.

公开(公告)号：US12064471B2

公开(公告)日：2024-08-20

申请号：US17178664

申请日：2021-02-18

Applicant: NUTRAMAX LABORATORIES, INC.

Inventor： Brian Cornblatt ,  Grace Cornblatt ,  Anton Bzhelyansky ,  Robert Henderson

IPC: A23L33/105 ,  A61K9/00 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/00 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K38/47 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06

CPC classification number: A61K38/47 ,  A23L33/105 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/28 ,  A61K31/19 ,  A61K31/194 ,  A61K31/26 ,  A61K31/357 ,  A61K31/375 ,  A61K31/7028 ,  A61K31/716 ,  A61K33/06 ,  A61K36/06 ,  A61K36/07 ,  A61K36/28 ,  A61K36/31 ,  A61K45/06 ,  A61K47/42 ,  A61P3/06 ,  C12Y302/01147 ,  A23V2002/00 ,  A61K36/31 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K31/7028 ,  A61K2300/00 ,  A61K38/47 ,  A61K2300/00 ,  A61K31/375 ,  A61K2300/00 ,  A61K31/26 ,  A61K2300/00 ,  A61K36/28 ,  A61K2300/00 ,  A61K36/06 ,  A61K2300/00 ,  A61K36/07 ,  A61K2300/00

Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a β-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.

公开(公告)号：US12064436B2

公开(公告)日：2024-08-20

申请号：US16619526

申请日：2018-06-12

Applicant: SERVIER PHARMACEUTICALS LLC

Inventor： Joshua Murtie ,  Nelamangala Nagaraja ,  Brandon Nicolay ,  David Schenkein ,  Katharine Yen

IPC: C07D401/04 ,  A61K31/53 ,  A61K45/06 ,  A61P35/00 ,  A61K41/00

CPC classification number: A61K31/53 ,  A61P35/00 ,  A61K41/0038 ,  A61K31/53 ,  A61K2300/00

Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.

公开(公告)号：US12059465B2

公开(公告)日：2024-08-13

申请号：US15823151

申请日：2017-11-27

Applicant: Mars, Incorporated

Inventor： Edward Russell Cox ,  Douglas Joseph Dobrozsi ,  Thomas Edward Huetter ,  Allan John Lepine ,  Susan Ruth Beyer

IPC: A23K20/24 ,  A23K20/20 ,  A23K40/30 ,  A23K50/42 ,  A23K50/45 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/32 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K45/06

CPC classification number: A61K45/06 ,  A23K20/30 ,  A23K40/30 ,  A23K50/42 ,  A23K50/45 ,  A61K31/28 ,  A61K31/30 ,  A61K31/315 ,  A61K31/32 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K31/28 ,  A61K2300/00 ,  A61K31/30 ,  A61K2300/00 ,  A61K31/315 ,  A61K2300/00 ,  A61K31/32 ,  A61K2300/00 ,  A61K33/24 ,  A61K2300/00 ,  A61K33/30 ,  A61K2300/00 ,  A61K33/32 ,  A61K2300/00 ,  A61K33/34 ,  A61K2300/00 ,  A61K33/42 ,  A61K2300/00

Abstract: Edible compositions are provided and comprise a soluble mineral component and/or a phosphate component in amounts effective for use as an oral medicament. The soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof. The edible compositions are advantageously companion animal chews, treats or supplements. Further disclosed are methods of making the chews, treats or supplements as are methods of treating conditions of the oral cavity.

公开(公告)号：US12059016B2

公开(公告)日：2024-08-13

申请号：US15527860

申请日：2015-11-09

Applicant: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.

Inventor： Denis Breuille ,  Etienne Pouteau ,  Simina Florentina Popa Nita ,  Laurence Donato-Capel

IPC: A23L33/19 ,  A23C9/13 ,  A23K20/147 ,  A23K20/163 ,  A23L33/00 ,  A23L33/21 ,  A61K35/20 ,  A61K38/01

CPC classification number: A23L33/19 ,  A23C9/1307 ,  A23K20/147 ,  A23K20/163 ,  A23L33/21 ,  A23L33/30 ,  A23L33/40 ,  A61K35/20 ,  A61K38/018 ,  A23V2002/00 ,  A23V2200/00 ,  A23V2002/00 ,  A23V2200/00 ,  A23V2200/316 ,  A23V2250/5072 ,  A23V2250/54252 ,  A61K38/018 ,  A61K2300/00

Abstract: The present invention relates to the treatment or prevention of conditions linked to reduced muscle mass or reduced muscle protein synthesis rate. A subject matter of the invention is a composition comprising complexes of whey protein micelles and pectin for use in the treatment or prevention of a condition selected from the group consisting of sarcopenia, muscle atrophy and negative nitrogen balance. Further aspects of the invention relate to the non-therapeutic use of a composition comprising complexes of whey protein micelles and pectin and a food composition.

公开(公告)号：US12054447B2

公开(公告)日：2024-08-06

申请号：US17730948

申请日：2022-04-27

Applicant: City of Hope

Inventor： Linda H. Malkas ,  David Horne ,  Robert J. Hickey ,  Long Gu

IPC: C07C233/76 ,  A61K31/167 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4725 ,  A61K33/243 ,  A61P35/00 ,  A61P35/02 ,  C07C237/22 ,  C07D213/68 ,  C07D217/26 ,  C07D401/12

CPC classification number: C07C233/76 ,  A61K31/167 ,  A61K31/4409 ,  A61K31/4418 ,  A61K31/4725 ,  A61K33/243 ,  A61P35/00 ,  A61P35/02 ,  C07C237/22 ,  C07D213/68 ,  C07D217/26 ,  C07D401/12 ,  A61K33/24 ,  A61K2300/00 ,  A61K31/4725 ,  A61K2300/00 ,  A61K31/4418 ,  A61K2300/00

Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.

公开(公告)号：US12053527B2

公开(公告)日：2024-08-06

申请号：US17383494

申请日：2021-07-23

Applicant: Children's Medical Center Corporation ,  Massachusetts Institute of Technology

Inventor： Daniel S. Kohane ,  Rong Yang ,  Lily Yun Lin

IPC: A61K47/34 ,  A61K9/00 ,  A61K9/06 ,  A61K9/46 ,  A61K31/407 ,  A61K31/424 ,  A61K31/431 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/573 ,  A61K38/12 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P27/16 ,  A61P31/04 ,  C08G65/335 ,  C08G79/04

CPC classification number: A61K47/34 ,  A61K9/0046 ,  A61K9/06 ,  A61K31/407 ,  A61K31/424 ,  A61K31/431 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/573 ,  A61K38/12 ,  A61K45/06 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P27/16 ,  A61P31/04 ,  C08G65/3355 ,  C08G79/04 ,  A61K31/445 ,  A61K2300/00 ,  A61K31/573 ,  A61K2300/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/424 ,  A61K2300/00 ,  A61K31/431 ,  A61K2300/00 ,  A61K31/4709 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/5383 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for delivery of therapeutic agents across an barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel at a suitable gelation temperature and rheological properties for use in drug delivery, and in some cases, the gelation temperature and rheological properties are not significantly changed from those of the composition without the permeation enhancer. The invention also provides a matrix forming agent and compositions thereof. Such compositions are particularly useful in the treatment of otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.

公开(公告)号：US12053508B2

公开(公告)日：2024-08-06

申请号：US17891835

申请日：2022-08-19

Applicant: Hybrid Medical, LLC

Inventor： Jeffry Twidwell ,  Joel Buckley ,  Harold Hoium

IPC: A61K38/44 ,  A61K9/00 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90

CPC classification number: A61K38/446 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/12 ,  A61K31/277 ,  A61K31/40 ,  A61K31/4422 ,  A61K31/554 ,  A61K35/57 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/24 ,  C07D211/90 ,  C12Y115/01001 ,  A61K38/446 ,  A61K2300/00 ,  A61K31/4422 ,  A61K2300/00 ,  A61K31/554 ,  A61K2300/00 ,  A61K31/277 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K35/57 ,  A61K2300/00 ,  A61K38/212 ,  A61K2300/00

Abstract: The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites.

公开(公告)号：US12048769B2

公开(公告)日：2024-07-30

申请号：US16938443

申请日：2020-07-24

Applicant: Nalpropion Pharmaceuticals LLC

Inventor： Anthony A McKinney ,  Gary D. Tollefson ,  Eckard Weber ,  Richard Soltero

IPC: A61K9/24 ,  A61J1/03 ,  A61J7/04 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/35 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/7048 ,  A61K45/06 ,  B65D75/36

CPC classification number: A61K9/209 ,  A61J1/035 ,  A61J7/04 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/35 ,  A61K31/42 ,  A61K31/423 ,  A61K31/485 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/7048 ,  A61K45/06 ,  B65D75/36 ,  A61J7/0454 ,  A61K31/135 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/35 ,  A61K2300/00 ,  A61K31/42 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00

Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

公开(公告)号：US12048723B2

公开(公告)日：2024-07-30

申请号：US17989513

申请日：2022-11-17

Applicant: MARY KAY INC.

Inventor： Tiffany Florence

IPC: A61K36/28 ,  A61K8/34 ,  A61K8/36 ,  A61K8/49 ,  A61K8/63 ,  A61K8/9711 ,  A61K8/9728 ,  A61K8/9761 ,  A61K8/9767 ,  A61K8/9789 ,  A61K8/9794 ,  A61K9/00 ,  A61K9/107 ,  A61K31/047 ,  A61K31/20 ,  A61K31/401 ,  A61K36/31 ,  A61Q19/00

CPC classification number: A61K36/28 ,  A61K8/345 ,  A61K8/361 ,  A61K8/4913 ,  A61K8/63 ,  A61K8/9711 ,  A61K8/9728 ,  A61K8/9761 ,  A61K8/9767 ,  A61K8/9789 ,  A61K8/9794 ,  A61K9/0014 ,  A61K9/107 ,  A61K31/047 ,  A61K31/20 ,  A61K31/401 ,  A61K36/31 ,  A61Q19/007 ,  A61K36/28 ,  A61K2300/00 ,  A61K36/31 ,  A61K2300/00 ,  A61K31/401 ,  A61K2300/00 ,  A61K31/20 ,  A61K2300/00 ,  A61K31/047 ,  A61K2300/00

Abstract: Disclosed is a method for moisturizing skin in need thereof, the method comprising topically applying to the skin a composition that includes effective amounts of an extract from Echinacea purpurea, an extract from Silybum marianum, and glycerin, wherein topical application of the composition activates human cannabinoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the skin and treats the skin.